Lipid-lowering effects of oleanolic acid in hyperlipidemic patients.
10.1016/S1875-5364(18)30065-7
- Author:
Han-Qiong LUO
1
;
Jie SHEN
2
;
Cai-Ping CHEN
1
;
Xiao MA
2
;
Chao LIN
1
;
Qiong OUYANG
1
;
Chun-Xiao XUAN
1
;
Jine LIU
1
;
Hong-Bin SUN
3
;
Jun LIU
4
Author Information
1. Jiangsu Key Laboratory of Drug Screening and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
2. First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
3. Jiangsu Key Laboratory of Drug Screening and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China. Electronic address: hbsun2000@yahoo.com.
4. Jiangsu Key Laboratory of Drug Screening and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China. Electronic address: junliu@cpu.edu.cn.
- Publication Type:Clinical Trial
- Keywords:
Clinic;
DNA microarray;
Hyperlipidemia;
Oleanolic acid;
Pathway analysis
- MeSH:
China;
Computational Biology;
Drugs, Chinese Herbal;
pharmacology;
therapeutic use;
Female;
Gene Expression Profiling;
Gene Expression Regulation;
drug effects;
Humans;
Hyperlipidemias;
blood;
drug therapy;
genetics;
metabolism;
Lipid Metabolism;
drug effects;
Male;
Middle Aged;
Oleanolic Acid;
pharmacology;
therapeutic use;
RNA, Messenger;
genetics;
Treatment Outcome
- From:
Chinese Journal of Natural Medicines (English Ed.)
2018;16(5):339-346
- CountryChina
- Language:English
-
Abstract:
Oleanolic acid (OA) is a pentacyclic triterpenoid compound extracted from olea europaeal, a traditional Chinese medicine herb. OA has been used in the clinic as a hepatoprotective medicine in China since 1970s. In our previous study, we observed that OA could ameliorate hyperlipidemia in animal models. In the present study, we conducted a small-scale clinical trial to evaluate the hypolipidemia effect of OA in hyperlipidemic patients. Hyperlipidemic patients were administrated with OA for four weeks (4 tablets once, three times a day). The blood samples of the patients were collected before and after OA treatment. The biological parameters were measured. Furthermore, three patients' blood samples were studied with DNA microarray. After OA administration, the TC, TG, and HDLC levels in serum decreased significantly. DNA microarray analysis results showed that the expressions of 21 mRNAs were significantly changed after OA treatment. Bioinformatics analysis showed 17 mRNAs were up-regulated and 4 mRNAs were down-regulated significantly after OA treatment. Five mRNAs (CACNA1B, FCN, STEAP3, AMPH, and NR6A1) were selected to validate the expression levels by qRT-PCR. Therefore, OA administration differentially regulated the expression of genes involved in lipid metabolism. The data showed a clinical evidence that OA could improve hyperlipidemia and also unveiled a new insight into the molecular mechanisms underlying the pharmacological effect of OA on hyperlipidemia.
